COVID-19: Trump Still Hasn’t Pulled Trigger On Defense Production Act
Prez says the threat of company “nationalization” under the Defense Protection Act “sent tremors through our business community and through our country”
• By Shawn M. Schmitt
President Trump still hasn’t used the Defense Production Act to address US medical device shortages despite invoking the law on 18 March. The DPA gives the government broad authority to, among other things, push manufacturers to make particular products in a time of great national need. At a 22 March press conference, Trump said he’s leery of doing that because “the concept of nationalizing our businesses is not a good concept. If you go the nationalization route, we’re going to tell a company to make a ventilator – they don’t even know what a ventilator is.”
Despite invoking the Defense Production Act four days ago to help the US in its efforts to tamp down the coronavirus pandemic, President Trump has not yet used the law to address critical medical supply shortages.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
The US Medicare agency will hold three public meetings in June and July addressing tremor treatment devices and clinical diagnostic lab tests. The first meeting on June 25 will focus on endpoints for Parkinson’s device trials, while subsequent meetings will address payment rates and codes for laboratory tests.
Congress has launched an inquiry into 23andMe amid privacy concerns following its bankruptcy, particularly regarding the potential sale of sensitive user data. Additionally, a Cybernews report gave 40 DNA testing firms an average cybersecurity grade of D, citing widespread vulnerabilities and data breaches, along with inadequate public information about their security practices.
As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.
Many of the hundred-plus commenters to the FDA's draft guidance on AI in medical product regulation said the document was a good start but needed additional clarity and more concrete examples. Stakeholders recommended the inclusion of case studies, metrics, and clearer guidelines to enhance the utility of the guidance, which is seen as a vital step for AI integration in healthcare.
HHS Secretary Robert F. Kennedy Jr. urged FDA staff to resist the “deep state” and “crony capitalism,” and focus on improving the health of America’s children. “You're not here to take orders,” he said and urged FDA staff to speak up if they see wrongdoing.
